RetInSight is the first company to introduce an MDR CE-certified AI-solution for use in clinical routine by eye care specialists. The company was founded in April 2020 as a spin-off from the Department of Ophthalmology & Optometry of the Medical University of Vienna, Austria. RetInSight develops transformational AI-based medical devices and services using OCT images and does this with a clear vision: living longer shall not mean seeing less.
To accomplish this goal, RetInSight develops certified AI-based solutions for therapeutic monitoring and diagnostic screening according to the highest quality standards. RetInSight further owns an extensive library of validated algorithms for use in (bio)pharmaceutical clinical and scientific studies (CAIRE). Upon certification, these algorithms are made available for use in clinical routine, after already having been applied in large population-based data sets and presented in publications in peer-reviewed journals. In this way, RetInSight helps bridge the gap between superior outcomes observed in clinical trials and inferior benefits obtained at high cost in real life, for the most predominant retinal diseases of our times. And by bringing together the most advanced technologies in computer science, state-of-the-art clinical expertise as well as medical science, we are optimally positioned to help shape the future of precision medicine.
Therapeutic monitoring services for Ophthalmologists
Our AI solutions support the leading OCT devices and can be integrated into diverse ophthalmic software systems, such as PACS and EMR, reducing operational effort and cost, saving time for patient care. As a game changer in retinal disease management, RetInSight develops fully automated cloud-based algorithms to reliably identify, localize and quantify all types of pathologies and relevant biomarkers, e.g. fluid in routine OCT examinations.
Diagnostic screening services for Opticians and Optometrists
In a patient-centric manner, opticians and optometrists may cooperate and benefit from real-time OCT image analysis in a user-friendly and plausible format. Eye care professionals are empowered by an objective, quantifiable and reproducible evaluation of each individual patient‘s condition.
Founders and Team
Corinna zur Bonsen-Thomas
MANAGING PARTNER, CEO & FOUNDER
Corinna zur Bonsen-Thomas, RetInSight’s managing partner and CEO, is a legal executive with 30 years of experience in senior roles in the global pharmaceutical and medical device industry.
Since 2017 she has been an advisor and General Counsel for small businesses and start-ups focusing on medical software and digital image analysis (including Definiens AG; Smart Reporting GmbH). Corinna is a member of the supervisory board of Abivax, a French listed biotech company.
Dr.-Ing. Amir Sadeghipour
CHIEF TECHNOLOGY OFFICER & FOUNDER
Amir Sadeghipour completed his studies in computer science at the TU Berlin with a focus on ArtificiaI Intelligence and was awarded the “Best Doctoral Dissertation of 2015” at the Technical Faculty of Bielefeld University.
He has over 13 years of experience in research and development of AI methods and 6 years of working experience in the private sector. Amir led the software development at OPTIMA (Medical University of Vienna) for over 4 years, developing software and AI algorithms for ophthalmic image analyses. In addition, he served as the Head of IT at the VRC (Vienna Reading Center). He represents RetInSight’s technical-scientific competence as Chief Technology Officer responsible for AI research and development.
Hans Peter Schwarz, MD, Associate Professor of Medicine
MANAGING PARTNER, CFO & FOUNDER
Prof. Schwarz, a physician by training, is an accomplished healthcare executive with more than 30 years experience in the biopharmaceutical and device industry. Prior to joining RetInSight Dr. Schwarz held leadership roles with Baxter, Baxalta and Shire and served as a Member of the Board of Baxter AG in Vienna, the Management Board of the Baxter/Baxalta Austria Corporation, an operation with approx. 4300 employees in Austria.
In his role as Global VP Research and Development of Baxter BioScience, Dr. Schwarz was responsible for developing a strong product pipeline for Baxter BioScience bringing successfully biological products from discovery to global regulatory approval. Dr. Schwarz is managing partner and CFO of RetInSight.
Univ.-Prof. Dr. Ursula Schmidt-Erfurth
SCIENTIFIC AND MEDICAL ADVISOR & FOUNDER
As Co-founder and Member of the Advisory Board, Prof. Schmidt-Erfurth represents independent scientific and medical expertise and is one of the world’s leading specialists in the field of retina. She is Professor and Chair of the Department of Ophthalmology at the Medical University of Vienna, Adjunct Professor of Ophthalmology at Northwestern University and a Full Member of the Austrian Academy of Sciences.
She is Founder & Director of the VRC (Vienna Reading Center), a digital platform for image analyses connected to 800 clinical centers world-wide. She serves as the medical director of the Christian Doppler Laboratory for ophthalmic image analysis (OPTIMA), pioneering AI in diagnostic and therapeutic ophthalmology and is holding several patents in imaging and AI. She has published over 450 papers in the world’s leading ophthalmological journals.
RetInSight and the Medical University are partners under a collaboration agreement.
Prof. Schmidt-Erfurth was the former president of EURETINA, the European Society of Retina Specialists. She is a member of the American Academy of Ophthalmology, the Association for Research in Vision and Ophthalmology, the Retina Society, the Macula Society, the American Society of Retina Surgeons and the Jules Gonin Club.
She is world renowned for inventing and introducing Photodynamic Therapy for AMD which became the gold standard of treatment for many years.
CHIEF COMMERCIAL OFFICER (CCO)
After having pioneered in a different segment of the ophthalmic AI arena in Europe for several years, which involved a close collaboration with the ophthalmology department of the Medical University of Vienna and RetInSight co-founder Prof. Schmidt-Erfurth, Arlette decided to shift her focus to the domain of AI that enables precision medicine in ophthalmology and joined RetInSight.
Arlette has a long track record in life science product launches (pharmaceuticals, medical devices, e-health apps and AI), with international companies of varying sizes and increasing levels of responsibility. She lives in The Netherlands, which will be her place of business when not visiting the RetInSight HQ, customers, business partners and other stakeholders. In her role with RetInSight, Arlette sees a perfect opportunity to capitalize on her combined experience and for the benefit of healthcare providers, patients and payors in need of state-of-the-art AI to improve the efficiency of pharmaceutical care in ophthalmology without compromising on quality and safety.
HEAD OF QUALITY MANAGEMENT & REGULATORY AFFAIRS
Thomas Grundnig has over 20 years of experience with Quality Management and Regulatory Affairs in the medical industry. He has extensive expertise with medical device development, production, and commercialization.
In particular, he is an expert in medical device certification according to previous and current EU regulations, which include technical documentation compliance, software development lifecycle requirements, risk management, usability, post-market surveillance, and post-market clinical follow-up. Thomas acts as Head of Quality Management and Regulatory Affairs.
Martina Neschi, PhD
HEAD OF CLINICAL TRIAL SERVICES
Martina Neschi gained her PhD in Biomedicine and Biotechnology granted by the DOC-fFORTE Scholarship of The Austrian Academy of Sciences.
After dedicating several years to basic research, she joined the Department of Ophthalmology at MUV where she focused on study coordination of investigator-initiated studies and sponsor-initiated trials. In this capacity, she worked closely with pharmaceutical partners, ethic committees, federal agencies, ophthalmologists and physicians of complementary discipline, and image grading experts. As Head of Clinical Trial Services at RetInSight, Martina is responsible for pharma alliance and project management.
- Univ.-Prof. Dr. Ursula Schmidt-Erfurth
Professor and Chair, Medical University Vienna, Department of Ophthalmology and Optometry
- Univ.-Prof. Dr. Sepp Hochreiter
Director, Institute for Machine Learning, Johannes Kepler University Linz, Austria
- Dr. Wolfgang Hackel
CFO Global R&D, Takeda
About the RetInSight logo
The logo is the identification mark of the RetInSight company. It carries our content and visual identity to the outside and consists of two elements: figurative mark and word mark.
The figurative mark represents the eye in the form of a 3-dimensional hemisphere. The small colored iris dots represent the biomarker. This is how the icon visualizes the core competence of RetInsight: the AI-based analysis of 3-dimensional OCT images.
The word mark RetInSight is set in italics and underlines the dynamic of the logo. Through the capital letters in the lettering the idea behind the name, combining the terms Retin(a) and Insight, is clarified.
Our logo expresses what RetInSight is all about: the accuracy and speed of the analysis process enabled by artificial intelligence, and the innovative strength of the company.